Patients failing standard diabetes drugs enter 2 Biomea studies Two trials target patients uncontrolled on GLP-1 therapy or insulin-deficient diabetes, with about 60 patients each and topline data due in 4Q 2026.

#BMEA Biomea Fusion Announces First Patient Dosed in Newly Initiated Phase II Programs Enrolling Type 2 Diabetes Patients Failing on Standard-of-Care Therapies

www.stocktitan.net/news/BMEA/biomea-fusion-...

Biomea Fusion Reports Full Year 2025 Financial Results and Corporate Highlights Initiated two Phase II trials COVALENT-211 and COVALENT-212 (icovamenib in type 2 diabetes) with 26-week primary endpoint data anticipated in the fourth quarter of 2026 Completed 52-week follow-up from Phase II trial COVALENT-112 (icovamenib in type 1 diabetes) with data expected in the second

#BMEA Biomea Fusion Reports Full Year 2025 Financial Results and Corporate Highlights

www.stocktitan.net/news/BMEA/biomea-fusion-...

Original post on benzinga.com

Biomea Fusion Reports Positive Phase II Data For Diabetes Drug Icovamenib Biomea Fusion (NASDAQ: BMEA) shares rose Friday after the company reported positive Phase II data for icovamenib in type 2 ...

#benzai #BMEA #Equities #News #Type #2 #Diabetes #Health […]

[Original post on benzinga.com]

Biomea Fusion Enters 2026 Focused on Executing Key Icovamenib and BMF-650 Milestones Biomea Fusion (Nasdaq: BMEA) outlined 2026 priorities focused on advancing icovamenib and BMF-650. Icovamenib, a potential first-in-class covalent menin inhibitor, showed durable glycemic benefit at 52 weeks after a 12-week regimen and completed a 60-participant food-effect study with optimal exposure when dosed within 30 minutes after a meal. Chronic toxicology studies in two species were completed and >400 subjects have been dosed. BMF-650, an oral next-generation GLP-1 receptor agonist, will report 28-day weight-loss data from Phase I in Q2 2026. Company expects Phase II enrollments in Q1 2026 and HbA1c readouts in Q4 2026.

#BMEA Biomea Fusion Enters 2026 Focused on Executing Key Icovamenib and BMF-650 Milestones

www.stocktitan.net/news/BMEA/biomea-fusion-...

Biomea Fusion Presents COVALENT-111 Study Results at the 23rd World Congress on Insulin Resistance, Diabetes & Cardiovascular Disease (WCIRDC) Biomea Fusion (NASDAQ: BMEA) presented COVALENT-111 results at WCIRDC (Dec 3-6, 2025) showing durable glycemic and C‑peptide improvements with icovamenib, a selective menin inhibitor for insulin‑deficient type 2 diabetes. Data reported durable and continuous treatment effect at week 52 (9 months post last dose), exposure‑response for HbA1c, improved long‑term insulin secretion, benefit in prior GLP‑1 “failures,” and generally good tolerability with no related serious adverse events or AE‑related discontinuations. The abstract will appear in Metabolism: Experimental and Clinical and the presentation will be posted on Biomea Fusion’s investor relations site.

#BMEA Biomea Fusion Presents COVALENT-111 Study Results at the 23rd World Congress on Insulin Resistance, Diabetes & Cardiovascular Disease (WCIRDC)

www.stocktitan.net/news/BMEA/biomea-fusion-...

Biomea Fusion Announces Oral Presentation of Icovamenib at the 23rd World Congress on Insulin Resistance, Diabetes & Cardiovascular Disease (WCIRDC) Biomea Fusion (Nasdaq: BMEA) will deliver an oral presentation of Week 52 long-term follow up data for icovamenib at the 23rd World Congress on Insulin Resistance, Diabetes & Cardiovascular Disease (WCIRDC) in Los Angeles on Dec 3-6, 2025. The oral talk (Abstract #0062COVALENT-111) is titled "Durable Glycemic and C-Peptide Improvements with Icovamenib, a Menin Inhibitor Targeting β-Cell Restoration in Insulin-Deficient Type 2 Diabetes" and is scheduled for Dec 5, 2025, 6:15 pm–7:45 pm PST. Biomea noted it is one of six oral presentations at the meeting and said poster and presentation materials will be available on the company website.

#BMEA Biomea Fusion Announces Oral Presentation of Icovamenib at the 23rd World Congress on Insulin Resistance, Diabetes & Cardiovascular Disease (WCIRDC)

www.stocktitan.net/news/BMEA/biomea-fusion-...

#BMEA Biomea Fusion Showcases Preclinical Advances for BMF-650 and Icovamenib with Low Dose Semaglutide at ObesityWeek® 2025

www.stocktitan.net/news/BMEA/biomea-fusion-...

Biomea Fusion Reports Third Quarter 2025 Financial Results and Corporate Highlights Advances diabetes and obesity programs with icovamenib demonstrating durable 52-Week Phase II data and with BMF-650, Biomea’s next-generation, oral small molecule glucagon-like peptide-1 (“GLP-1”) receptor agonist (“RA”), dosing its first patient in a Phase I clinical trial Presented preclinical

#BMEA Biomea Fusion Reports Third Quarter 2025 Financial Results and Corporate Highlights

www.stocktitan.net/news/BMEA/biomea-fusion-...

🎯 Momentum #Options Activity trade ideas! Heavy institutional #optionsvolume far above daily averag

🎯 Momentum #Options Activity trade ideas! Heavy institutional #optionsvolume far above daily average with strong consensus on direction.

PM Algo #TradeIdea from 🔥 INSIDERFINANCE.COM 🔥
#CRM, #BMEA, #PSQH, #ZIM, #TWLO

#OptionFlow #OptionsTrading #Trading

🚨 Institutions #optionsvolume surge detected! PM Top Momentum Activity from 🔥 INSIDERFINANCE.COM

🚨 Institutions #optionsvolume surge detected!

PM Top Momentum Activity from 🔥 INSIDERFINANCE.COM 🔥
1. #HTZ 9.9x
2. #DECK 7.4x
3. #CRM 6.8x
4. #BMEA 6.5x
5. #NNE 5.8x

#OptionFlow #OptionsTrading #Trading

Biomea Fusion Announces Proposed Public Offering of Securities Biomea Fusion (Nasdaq: BMEA) announced on Oct 6, 2025 that it has commenced an underwritten public offering of its common stock and accompanying warrants, with pre-funded warrants offered to certain investors in lieu of common stock. The company said it will grant underwriters a 30-day option to purchase up to an additional 15% of the shares and/or warrants as overallotment. All securities in the proposed offering are to be sold by Biomea and the offering is subject to market and other conditions, with no assurance it will be completed on specific terms or timing.The offering is being managed by Jefferies and will be made under an effective Form S-3 registration (filed Aug 5, 2025; declared effective Aug 15, 2025); a preliminary prospectus supplement will be filed with the SEC when available.

#BMEA Biomea Fusion Announces Proposed Public Offering of Securities

www.stocktitan.net/news/BMEA/biomea-fusion-...

Biomea Fusion (BMEA) Q2 Loss Drops 44% | The Motley Fool

#BMEA #f4d28d16-ca41-4a36-ab29-080c9bc049ca #data-news

Origin | Interest | Match

Biomea Fusion Reports Second Quarter 2025 Financial Results and Corporate Highlights Biomea Fusion (Nasdaq: BMEA) reported Q2 2025 financial results and key developments for its diabetes and obesity pipeline. The company presented three significant studies at ADA 2025 highlighting icovamenib's therapeutic potential in type 2 diabetes, showing durable HbA1c reduction and improved beta-cell function. Their next-generation oral GLP-1 receptor agonist, BMF-650, demonstrated up to 15% weight reduction in non-human primates.The company raised $42.8 million through a public offering, extending cash runway into H2 2026. Q2 2025 resulted in a net loss of $20.7 million, compared to $37.3 million in Q2 2024. Biomea reduced its workforce and expects quarterly operational expenses to be approximately 40% lower than the previous quarter.

#BMEA Biomea Fusion Reports Second Quarter 2025 Financial Results and Corporate Highlights

www.stocktitan.net/news/BMEA/biomea-fusion-...

Biomea Fusion Presents New Preclinical and Clinical Data on Icovamenib at the 85th Scientific Sessions of the American Diabetes Association (ADA) Biomea Fusion (BMEA) presented promising new data for icovamenib, their oral menin inhibitor, at the ADA Scientific Sessions. In clinical trials, icovamenib demonstrated significant efficacy in type 2 diabetes treatment, achieving a 1.0% placebo-adjusted HbA1c reduction and 55% C-peptide increase in insulin-deficient patients. When combined with low-dose semaglutide in preclinical studies, the treatment showed superior metabolic benefits including enhanced glycemic control, 60% lower fasting blood glucose, and greater body weight reduction while preserving lean mass. The Phase II COVALENT-111 trial revealed sustained benefits even after treatment discontinuation, with particularly strong results in patients using GLP-1 RA therapy. The drug demonstrated good tolerability with no significant adverse events or discontinuations.

#BMEA Biomea Fusion Presents New Preclinical and Clinical Data on Icovamenib at the 85th Scientific Sessions of the American Diabetes Association (ADA)

www.stocktitan.net/news/BMEA/biomea-fusion-...

PRISM Mid-Day Movers: Stock Dilution and Cannabis Earnings Drive Indices Lower
#BiomeaFusion #BMEA Falls 32% on Stock Offering Despite Promising Obesity Data
#AuroraCannabis #ACB Slides 20% Despite Record Revenue and Positive Free Cash Flow
prismmarketview.com/prism-mid-da...

A stethoscope resting on a digital stock chart display, symbolizing the intersection of biotechnology and financial performance, referencing Biomea Fusion.

#BiomeaFusion Nasdaq: #BMEA is back in motion.
After announcing a $40M public offering that sent shares lower, Biomea is rebounding following new preclinical data for its oral GLP-1 candidate BMF-650...
prismmarketview.com/biomea-fusio...

Biomea Fusion Announces Pricing of Public Offering of Securities Biomea Fusion (BMEA) has priced its public offering of securities, consisting of 19,450,000 shares of common stock and warrants, plus 550,000 pre-funded warrants with accompanying warrants. The combined offering price is $2.00 per share of common stock with warrant, and $1.9999 for each pre-funded warrant with warrant. The accompanying warrants have an exercise price of $2.50, are immediately exercisable, and expire in 18 months. The offering is expected to generate approximately $40 million in gross proceeds before deductions. Biomea has granted underwriters a 30-day option to purchase up to 3 million additional shares and/or warrants. The offering is expected to close on June 20, 2025, with Jefferies acting as the sole book-running manager.

#BMEA Biomea Fusion Announces Pricing of Public Offering of Securities

www.stocktitan.net/news/BMEA/biomea-fusion-...

Biomea Fusion Announces Proposed Public Offering of Securities Biomea Fusion (BMEA), a clinical-stage diabetes and obesity company, has announced a proposed public offering of common stock and warrants. The offering includes shares of common stock, pre-funded warrants, and accompanying warrants to purchase common stock. Biomea will grant underwriters a 30-day option to purchase up to 15% additional shares and pre-funded warrants. Jefferies is serving as the sole book running manager for the offering, which is expected to close around June 20, 2025. The securities will be offered through an effective shelf registration statement on Form S-3 filed with the SEC. The final size, terms, and completion of the offering are subject to market conditions.

#BMEA Biomea Fusion Announces Proposed Public Offering of Securities

www.stocktitan.net/news/BMEA/biomea-fusion-...

Biomea Fusion Highlights Early Signs of Efficacy for BMF-500 in Difficult-to-Treat Leukemia Biomea Fusion (Nasdaq: BMEA) shared new data at EHA 2025 showing early clinical activity from its investigational FLT3 inhibitor, BMF-500, in patients with rela

#BMEA presents new Phase 1 data for BMF-500 at #EHA2025 showing early signs of efficacy in hard-to-treat FLT3-mutant leukemia. Bone marrow blast reductions, CRi, and strong safety profile support ongoing development. Strategic partnerships ahead.
#biomeafusion
prismmarketview.com/biomea-fusio...

Biomea Fusion Presents Updated Preliminary Clinical Data for Covalent FLT3 Inhibitor BMF-500 in Relapsed or Refractory Acute Leukemia at EHA 2025 Biomea Fusion (NASDAQ: BMEA) presented updated clinical data for BMF-500, their covalent FLT3 inhibitor, in treating relapsed/refractory acute leukemia. The Phase I COVALENT-103 trial included 27 heavily pretreated patients, with 18 having FLT3 mutations. Key findings showed 9 of 11 evaluable FLT3m patients achieved bone marrow blast reduction, with one patient achieving complete remission with incomplete hematologic recovery (CRi) sustained for 6 cycles. The median overall survival was 3.8 months in Arm A and 3.5 months in Arm B, comparing favorably to historical 2.1 months survival. BMF-500 demonstrated good tolerability with no dose-limiting toxicities or QT prolongation. Following dose escalation completion, Biomea plans to conclude internal development and seek strategic partnerships for the program's advancement.

#BMEA Biomea Fusion Presents Updated Preliminary Clinical Data for Covalent FLT3 Inhibitor BMF-500 in Relapsed or Refractory Acute Leukemia at EHA 2025

www.stocktitan.net/news/BMEA/biomea-fusion-...

🚀 Exciting times for #BMEA! With AI-driven innovations boosting its market position, the stock shows strong bullish momentum. Consider entering at $2.45, targeting $2.70 & $3.00. Watch for short-term pullbacks, but the trend is positive! 📈 #InvestSmart #FeetrAI

🚀 Exciting times for #BMEA! With strong bullish momentum and tech/healthcare optimism, Biomea Fusion is on the rise. Consider a long position at $2.45, targeting $2.70 & $3.00. Stay sharp with a stop loss at $2.30. AI innovations could fuel the fire! 🔥 #Stocks #InvestSmart

🚀 Exciting times for #BMEA! With a 60% surge, AI-driven healthcare tech is fueling bullish vibes. RSI hints at more gains, but watch for pullbacks. Consider going LONG at $2.50, targeting $2.80 & $3.00. Stop loss at $2.30. Stay sharp on market moves! #FeetrAI #Stocks 📈

🚀 Exciting times for #BMEA! With AI-enhanced imaging tech driving momentum, Biomea Fusion is on the rise. 📈 Strong indicators suggest a bullish trend, but watch for short-term pullbacks. Entry at $2.48, targets at $2.75 & $3.00. Stay sharp! #StockMarket #AIInnovation

🚀 Exciting times for #BMEA! With AI-driven imaging advancements and strong technicals, this biotech gem is on a bullish run. Consider a LONG position at $2.48, targeting $2.70 & $2.90. But stay sharp—volatility looms! 📈 #FeetrAI #StockMarket #BiotechInnovation

🚀 Exciting times for #BMEA! With AI-driven healthcare buzz, Biomea Fusion is on the rise. Strong bullish momentum with an 8-day EMA at $2.07 and MACD support. Watch RSI for pullbacks. Consider entry at $2.45, targeting $2.70 & $3.00. Stop loss: $2.30. Stay sharp! 📈 #Stocks #AI

🚀 Exciting times for #BMEA! Biomea Fusion is riding a bullish wave with AI-driven medical imaging advancements. High volumes & positive sentiment push the stock up, despite global tensions. Consider a long at $2.55, targeting $3.00 & $3.20. Manage risk wisely! 📈 #FeetrAI

🎯 Momentum #Options Activity trade ideas! Heavy institutional #optionsvolume far above daily averag

🎯 Momentum #Options Activity trade ideas! Heavy institutional #optionsvolume far above daily average with strong consensus on direction.

PM Algo #TradeIdea from 🔥 INSIDERFINANCE.COM 🔥
#VTLE, #WMB, #BMEA, #UEC, #SIRI

#OptionFlow #OptionsTrading #Trading

🎯 Sweep Options Activity trade ideas! Institutions trading #options urgently with strong consensus

🎯 Sweep Options Activity trade ideas! Institutions trading #options urgently with strong consensus on direction.

PM Algo #TradeIdea from 🔥 INSIDERFINANCE.COM 🔥
#BMEA, #ENPH, #CLF, #MSTR, #MARA

#OptionFlow #OptionsTrading #Trading

SmCpStr Technicals – Technical Indicators for Small-cap Stocks

Small-cap stocks with improving money flow, Tues Jun 3rd - #ACMR #BMEA #CCB #ENUX #FONR #HOFT #IMAB #KPRX #MESO #NGNE #PLUS #VET #UTZ #TIXT #SRI #PKST #OLP #NTB #LXU #EXK #CNNE #BLND #XMTR #VRA #UCTT #SPWH - More: crystalequityresearch.com/SmCpStr/ - #smallcap